



Nevada State Purchasing Division
Department of Administration
515 E Musser St Ste 300
Carson City, NV 89701
purchasing.nv.gov
nevadaepro.com

Request for Information

Date 09/30/2026

Solicitation number 41NHA-S4034

Single point of contact name Heather Moon

Single point of contact email hmoon@admin.nv.gov

Requesting agency Nevada Health Authority, Medicaid – Prescription Drug Rebate

Request for information title Pharmaceutical Data and Retrospective Pricing Analytics SaaS

Response deadline date and time 10/29/2026 @ 2:00 P.M. P.S.T

This request for information (RFI) is available at nevadaepro.com as a bid solicitation.

Table of Contents

1.	Applicable regulations governing procurement	2
2.	Project overview	2
3.	Scope of work	2
4.	Cost	3
5.	Timeline	3
6.	Submission checklist.....	3

1. APPLICABLE REGULATIONS GOVERNING PROCUREMENT

- 1.1. All applicable Nevada Revised Statutes (NRS) and Nevada Administrative Code (NAC) documentation can be found at: www.leg.state.nv.us/law1.cfm.
- 1.2. Vendors are advised to review Nevada's ethical standards requirements, including but not limited to [NRS 281A](#), [NRS 333.800](#), and [NAC 333.155](#).
- 1.3. This solicitation is a request for information (RFI) only. It is not a solicitation for bids or proposals. No contract award will result from this RFI. Aggregate information from this RFI will be analyzed and may be used as budget justification or to develop a subsequent solicitation.
- 1.4. All information received in response to this solicitation is considered confidential business information by the Administrator of the Nevada State Purchasing Division of the Department of Administration. This solicitation will not lead to evaluation or award pursuant to [NRS 333.335\(7\)](#), so responses remain confidential.

2. PROJECT OVERVIEW

- 2.1. Pharmaceutical Data and Retrospective Pricing Analytics providing single preferred drug list management.
- 2.2. Requesting agency background
 - 2.2.1. NVHA Medicaid, Pharmacy Drug Rebate

3. SCOPE OF WORK

- 3.1. Summary
 - 3.1.1. Software as a Service provider (SaaS) that obtains general pharmaceutical data and retrospective pricing and synthesizes clinical pipeline data and medical/pharmacy benefit crosswalks specific to Medicaid into a single platform. This platform must be able to provide forward-looking, loss-of-exclusivity projections required for proactive Medicaid fiscal forecasting and single preferred drug list management and blends patent law with pharmacy clinical/financial forecasting. Provide comprehensive pharmacy and therapeutic management strategy, supporting formulary, clinical, contracting, and market-access decisions. Also provide In-depth analysis regarding drug availability, clinical data, clinical pipeline tracking, evidence-based clinical pathways, preferred products, and site of care, disease class-specific strategy reports, drug alerts, pipeline trend reports, and new-drug reviews, assessments of potential new brand product prevalence and pricing impacts prior to launch.
 - A. Optimize FTE resource allocation dedicated to forecasting, monitoring and validating drug pricing/coding and market insights
 - B. Proactively identify new cost saving, outcome improving management opportunities through enhanced visibility on the changing market landscape
 - C. Accurately forecast financial implications on shifts in the drug landscape
 - D. Inform your executives proactively on changes and opportunities in the pharmaceutical landscape
 - 3.1.2. Pharmaceutical Data and Retrospective Pricing Analytics Service as a Software platform (Saas) shall process data from thousands of sources, combine it with proprietary research, and works to normalize, analyze, and summarize it.
 - 3.1.3. SaaS shall provide visibility into the life cycle of drugs and biologics, from early-stage pipeline assets to mature, established products.
 - A. Brand, generic, and biosimilar launch tracking
 - B. Loss-of-exclusivity insight, timing, and analytics
 - C. Innovative drug pipeline tracking
 - D. Litigation analysis and forecasted litigation outcomes
 - E. Regulatory impacts
 - 3.1.4. SaaS shall combine advanced pharmaceutical landscape market visibility with a team of Executive Clinical Pharmacists

to provide comprehensive pharmacy and therapeutic management strategy, supporting formulary, clinical, contracting, and market-access decisions. SaaS shall provide around-the-clock access to the web platform, real-time alerts, comprehensive reports, new drug reviews, podcast episodes, and expert consultations.

- A. In-depth analysis regarding drug availability, clinical data, clinical pipeline tracking, evidence-based clinical pathways, preferred products, and site of care
- B. Disease class-specific strategy reports, drug alerts, pipeline trend reports, and new-drug reviews
- C. Assessments of potential new brand product prevalence and pricing impacts prior to launch
- D. Extensive trend analysis examining brand vs. generic clinical pathways, cost-effective therapies, and payer perspectives
- E. Pricing specific to competitive landscape including generic-launch projections, FDA action dates, sales, therapy costs, and price changes
- F. Trend reports highlighting disease classes and drug events important to payers, systems, and manufacturers throughout the country
- G. Clinical criteria, formulary coverage, step therapy, and limited distribution network tracking

3.1.5. Data Analytics shall provide Market and Financial Insights and Rebate Monitor resources maps unique, catalyst-driven forecast methodologies to critical points in product life cycles, providing clear, timely, and actionable forecasts. SaaS platform shall provide fully transparent forecasting platform:

- A. Comprehensive online database detailing critical forecast input data and discussion around key catalysts
- B. Timely alerts to track how shifts in key catalysts alter forecasts as market conditions change
- C. Forecast scorecards to quickly assess the most meaningful attributes of a launch
- D. Curated analogs with expert commentary based on critical forecast factors
- E. Consultations with experts writing the reports and developing the forecasts

3.1.6. SaaS platform shall offer a complete medical drug-code (HCPCS/CPT) validation solution that utilizes current guidelines to develop coding, billing, and reimbursement information to ensure efficiency, compliance, accuracy and strategy identification.

4. COST

4.1. Vendors to propose projected costs for this RFI.

5. TIMELINE

5.1. All questions shall be submitted using the bid Q&A feature in nevadaepro.com by the deadline below.

5.2. The following represents the proposed timeline for this project.

5.2.1. All times stated are Pacific Time (PT).

5.2.2. These dates represent a tentative schedule of events.

5.2.3. The State reserves the right to modify these dates at any time.

- A. Deadline for questionsNo later than 4:00 pm on 10/12/2026
- B. Answers posted On or about 10/15/2026
- C. Submission deadlineNo later than 2:00 pm on 10/29/2026

6. SUBMISSION CHECKLIST

6.1. This section identifies the information requested and how to respond.

6.1.1. Information should be submitted as a quote through nevadaepro.com.

6.1.2. Technical information and cost information should not be included in the same attachment.

6.1.3. All attachments should be flagged as confidential in nevadaepro.com.

6.1.4. Additional attachments may be included.